Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2020

View Archived Issues

SERPINB3 targeting proven useful for treating NASH

Benzodiazepine and barbiturate binding to GABA-A

Giving misfolded proteins a second chance

Agrin-culture grows cartilage

SCAD versus plaques in heart attacks

Zion initiates phase I study in U.S. with ZN-A-1041

FDA approves Detectnet

New personalized cystic fibrosis treatment treats Class V mutations

First patient dosed in triple combination study of COM-701 plus Opdivo and BMS-986207

Arcutis accelerates ARQ-151 into phase III trials for the treatment of atopic dermatitis

First phase I data presented for the neutrophil elastase inhibitor BI-1323495

Opaganib demonstrates complete inhibition of SARS-CoV-2 in vitro

First subject dosed in phase I study of ALLN-346

Positive and statistically significant topline data from the pivotal LOGICS study of Recorlev

Enrollment begins in phase I study of AG-946

Phase III trial of odevixibat in progressive familial intrahepatic cholestasis meets endpoints

Janssen describes new anti-hepatitis B virus compounds

Asceneuron discovers N-acetyl-beta-D-glucosaminidase inhibitors

Sichuan Kelun-Biotech Biopharmaceutical patents NLRP3 agonists

Results from a phase IIa POC trial of the oral adenosine A1 receptor antagonist PBF-680

New thyroid hormone receptor alpha/beta agonists discovered at Nanjing Ruijie Pharma

Cervello Therapeutics describes new Rho-associated protein kinase inhibitors

Immunocore's bispecific ImmTAV molecules eliminate HBV-infected cells

Argenx begins first-in-human study of ARGX-117

LNC obtains IND clearance for phase I trial of Xla-1 for obesity

FDA clears IND for phase I study of anti-CD19 CAR-T cell therapy CB-010 for B-NHL

FDA accepts IND for phase I study of ATA-2271 for advanced mesothelioma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026